Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-analysis

Prostate Cancer and Prostatic Diseases

Volumn 9, Issue 4, 2006, Pages 374-378

  Wang, Y ^a   Sun, G ^a   Pan, J G ^a   Guo, Z J ^a   Li, T ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AREA UNDER THE CURVE; CHI SQUARE TEST; CHINESE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ELECTRONIC MEDICAL RECORD; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZATION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; MALE; ODDS RATIO; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33751559738     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500906     Document Type: Review

References (16)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Press: Lyon, 2001. http://www.iarc.fr/globocan/globocan.html (accessed June 2003).
2. Gao HW, Li YL, Wu SH, Wang SH, Zhang HF, Pan YZ et al. Mass screening of prostate cancer in a Chinese population: The relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005; 7: 159-163.
3. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels. J Urol 1995; 154: 407-413.
4. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
5. Zamora J, Muriel A, Abraira V. Meta-Disc for Windows: A Software package for the Meta-analysis of Diagnostic Tests. XI Cochrane Colloquium Barcelona, 2003. http://www.hrc.es/investigacion/metadisc_en.html (accessed July 2005).
6. Zhang XC, Na YQ, Guo YL. Role of prostate specific antigen in the diagnosis of prostate carcinoma. Chin J Urol 2000; 21: 37-40 (in Chinese).
7. Ma LT, Wang YW, Li YP, Li Y, Wang XQ, Ni YY. The role of the ratio of free PSA and total PSA in diagnosing prostate carcinoma. J Xi'an Med Univ 2002; 23: 180-181 (in Chinese).
8. Zhou LQ, Chen WM, Na YQ, Huang YY, Feng T, Hao JR et al. Serum total PSA and the ratio of free to total PSA in patients of benign prostate hyperplasia and prostate cancer. Chin J Urol 2002; 23: 354-357 (in Chinese).
9. Huang X, Pan CK, Fu BQ, Qiu MX, Liao Y. Role of PSA, PSAD and fPSA/tPSA in diagnosis of prostate cancer. Med J West China 2003; 1: 13-15 (in Chinese).
10. Lin Y, Li LM, Qiang WM, Yu ST, Yan H, Hu ZD. The percentage of free to total prostate specific antigen used in detecting prostate cancer. Clin cancer China 2003; 30: 252-254 (in Chinese).
11. Zhu YK, Zhang Y, Yang GH, Quan TT, Qu L. The use and analysis of free to total prostate specific antigen for prostate diseases. Med J Practice 2003; 19: 866-867 (in Chinese).
12. Liu ZJ, Chen BH, Chen SA. The role of the ratio of free PSA and total PSA in diagnosis of prostate cancer. J Pract Med Tech 2004; 11: 569-571 (in Chinese).
13. Gao ZW, Liu G, Sheng BW. Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia. Chin J Cancer 2004; 23: 701-703 (in Chinese).
14. Guan LM, Li SJ. Detecting free to total prostate specific antigen for the diagnosis of prostate carcinoma. J Dalian Med Univ 2005; 27: 54-56 (in Chinese).
15. Chen GJ, Lu JH, Yang Y, Dong CL. Serum tPSA, f/t ratio in diagnosis of prostate cancer and its positive alarm value. Med J CPAPF 2005; 16: 174-176 (in Chinese).
16. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: Systematic review and meta-analysis. Eur Urol 2005; 48: 386-399.